Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Deciphera Pharmaceuticals, Inc. (DCPH) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/09/2023 8-K Quarterly results
Docs: "Deciphera Pharmaceuticals Announces Second Quarter 2023 Financial Results"
08/03/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Deciphera Pharmaceuticals Announces Retirement of Daniel L. Flynn, Ph.D., and Appointment of Dashyant Dhanak, Ph.D., as Executive Vice President and Chief Scientific Officer"
05/03/2023 8-K Quarterly results
02/07/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results"
01/20/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Underwriting Agreement",
"Opinion of Goodwin Procter LLP"
01/18/2023 8-K Quarterly results
01/03/2023 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits  I...
Docs: "Deciphera Pharmaceuticals Announces Planned 2023 Corporate Milestones to Support Continued Evolution to Multi-Product Company",
"Summary of INTRIGUE Efficacy Results of ctDNA Analysis for Patients with Mutations in KIT Exon 11 and 17/18 Only Ripretinib Sunitinib Hazard Ratio/Response Difference Median Progression-Free Survival 14.2 months 1.5 months 0.22 , nominal p value Objective Response Rate 44.4% 0% 44.4% nominal p value = 0.0001 Overall Survival Not Estimable 17.5 months 0.34 , nominal p value = 0.0061 Notes: Data cut as of September 1, 2021; Data cut as of September 1, 2022. Based on the results of the ctDNA analysis and discussions with regulators, the Company plans to initiate the INSIGHT pivotal Phase 3 clinical study of QINLOCK versus sunitinib in second-line GIST patients with mutations in KIT exon 11 and 17/18 only. In the planned study, approximately 54 patients will be randomized 2:1 to either QINLOCK..."
11/03/2022 8-K Quarterly results
09/12/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Deciphera Pharmaceuticals, Inc. Presents Initial Phase 1 Single Agent Dose Escalation Data for First-in- Class ULK Inhibitor of Autophagy, DCC-3116, at the European Society for Medical Oncology Congress 2022",
"Deciphera Pharmaceuticals, Inc. Presents Updated Phase 1/2 Data for Vimseltinib in TGCT at the European Society for Medical Oncology Congress 2022"
08/04/2022 8-K Quarterly results
Docs: "Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2022 Financial Results"
06/24/2022 8-K Quarterly results
05/04/2022 8-K Quarterly results
04/26/2022 8-K Results of Operations and Financial Condition, Other Events  Interactive Data
02/11/2022 8-K Quarterly results
02/08/2022 8-K Quarterly results
01/24/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Deciphera Pharmaceuticals Presents Results from the INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session"
01/10/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2022 Corporate Milestones"
11/30/2021 8-K Cost Associated with Exit or Disposal Activities, Other Events, Financial Statements and Exhibits  Interactiv...
Docs: "Deciphera Pharmaceuticals Announces Restructuring to Prioritize Clinical Development Programs and Streamline Commercial Operations"
11/22/2021 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Deciphera Receives European Commission Approval of QINLOCK ® for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor"
11/10/2021 8-K Other Events  Interactive Data
11/05/2021 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Deciphera Pharmaceuticals Announces Top-line Results from the INTRIGUE Phase 3 Clinical Study"
11/02/2021 8-K Quarterly results
Docs: "Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2021 Financial Results"
09/29/2021 8-K/A Quarterly results
09/17/2021 8-K Quarterly results
09/17/2021 8-K Quarterly results
08/03/2021 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2021 Financial Results"
06/25/2021 8-K Quarterly results
05/04/2021 8-K Quarterly results
03/31/2021 8-K Quarterly results
02/09/2021 8-K Quarterly results
01/11/2021 8-K Quarterly results
11/30/2020 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Deciphera Pharmaceuticals Completes Target Enrollment in the INTRIGUE Phase 3 Clinical Study of QINLOCK ® in Patients with Second-Line Gastrointestinal Stromal Tumor"
11/12/2020 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Presentation from November 11, 2020, filed herewith"
11/05/2020 8-K Quarterly results
Docs: "Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2020 Financial Results"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy